PT-141, also known as Bremelanotide, has been a beacon of hope for women suffering from Hypoactive Sexual Desire Disorder (HSDD), a condition characterized by a persistent lack of interest in sex that causes personal distress. Marketed under the brand name Vyleesi, PT-141 is the first and only as-needed treatment that has been FDA-approved for premenopausal women with acquired, generalized HSDD. This article provides a comprehensive guide to the PT-141 sexual health protocol for women.
Understanding HSDD and How PT-141 Can Help
HSDD is a complex condition that can have a significant impact on a woman's quality of life. It is not simply a matter of low libido; it is a distressing lack of sexual desire that is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.
PT-141 works by activating melanocortin receptors in the brain, which are known to play a key role in regulating sexual desire and arousal. By targeting these receptors, PT-141 can help to restore sexual desire and improve the overall sexual experience for women with HSDD. [1]
The PT-141 Protocol for Women
The PT-141 protocol for women is designed to be a safe and effective way to improve sexual function. It is important to follow the prescribed dosage and administration guidelines to maximize benefits and minimize potential side effects.
Dosage and Administration
PT-141 is administered via a pre-filled autoinjector, making it easy and convenient to use. The recommended dose is 1.75 mg, injected subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity.
| Dosage | Administration |
|---|---|
| 1.75 mg | Subcutaneous injection, as needed |
Timing and Frequency
PT-141 should be taken on an as-needed basis, and it is recommended to use no more than one dose within a 24-hour period and no more than eight doses per month. The effects of PT-141 can begin within 45 minutes and last for 12 hours or more.
Potential Benefits of PT-141 for Women
- Increased Sexual Desire: PT-141 has been shown to significantly increase sexual desire in women with HSDD.
- Reduced Distress: By improving sexual desire, PT-141 can also help to reduce the distress associated with HSDD.
- Improved Sexual Satisfaction: Many women report an improvement in overall sexual satisfaction while using PT-141.
Key Takeaways
- PT-141 is an FDA-approved treatment for premenopausal women with HSDD.
- It works by activating melanocortin receptors in the brain to increase sexual desire.
- The recommended dose is 1.75 mg, taken as needed.
- PT-141 can help to improve sexual desire, reduce distress, and increase sexual satisfaction in women with HSDD.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
Citations
- Clayton, A. H., et al. "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial." Women's Health 12.3 (2016): 325-337. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384512/
- Kingsberg, S. A., et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized, Multicenter, Placebo-Controlled Trials." Obstetrics and gynecology 134.5 (2019): 899. https://journals.lww.com/greenjournal/Fulltext/2019/11000/Bremelanotide_for_the_Treatment_of_Hypoactive.5.aspx
- FDA. "Vyleesi (bremelanotide) injection, for subcutaneous use." https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210719s000lbl.pdf
